抗结核药物性肝损伤的新型生物标志物研究进展  

Progress in novel biomarkers of anti-tuberculosis drug-induced liver injury

作　　者：王乐乐 刘松涛 唐神结[3] 李佩波 Wang Lele;Liu Songtao;Tang Shenjie;Li Peibo(Tuberculosis Research Units,Chongqing Public Health Medical Center,Chongqing 400036,China;Chongqing Public Health Medical Center,Chongqing 400036,China;Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Research Institute,Beijing 101149,China)

机构地区：[1]重庆市公共卫生医疗救治中心结核病研究室,重庆400036 [2]重庆市公共卫生医疗救治中心,重庆400036 [3]首都医科大学附属北京胸科医院、北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中华结核和呼吸杂志》2024年第5期469-474,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家传染病临床重点专科建设项目;重庆市公共卫生重点专科(学科)建设项目;重庆市科卫联合医学科研项目(2023MSXM017)。

摘　　要：抗结核药物性肝损伤(ATB-DILI)是结核病患者在抗结核治疗过程中最常见的不良反应。目前ATB-DILI的诊断主要依赖于转氨酶等传统生物标志物,但这些指标对肝毒性特异性低,不能解释肝损伤机制,无法预测ATB-DILI的早期发病。本文通过ATB-DILI早期预测、严重程度预测以及治疗和预防三个方面,对目前有潜在前景的ATB-DILI生物标志物作一阐述。Anti-tuberculosis drug-induced liver injury(ATB-DILI)is the most common adverse reaction during anti-tuberculosis therapy in tuberculosis patients.At present,the diagnosis of ATB-DILI is mainly based on traditional biomarkers such as transaminases,but these indicators have low specificity for liver toxicity,they cannot explain the mechanism of liver injury and the early onset of ATB-DILI.Based on the prediction of disease severity,treatment and prevention,this paper described the current potential biomarkers of ATB-DILI.

关 键 词：生物标志物 结核病患者 抗结核药物性肝损伤 抗结核治疗 早期预测 肝毒性 不良反应 DILI 

分 类 号：R575[医药卫生—消化系统] R52[医药卫生—内科学]